Multicenter Japanese Clinical Trial Suggests Probiotic Therapy Drastically Reduces Recurrence Rates of Spontaneous Preterm Births

New research from Japan shows probiotics containing Clostridium butyricum significantly reduce the recurrence of spontaneous preterm delivery.

By: AXL Media

Published: Mar 30, 2026, 4:03 PM EDT

Source: Information for this report was sourced from University of Toyama

Addressing the Global Challenge of Neonatal Mortality

Preterm birth remains a primary driver of neonatal illness and mortality, frequently resulting in long-term complications such as respiratory distress and neurological injury. For women with a history of spontaneous preterm delivery, the risk of recurrence in subsequent pregnancies is a persistent concern in obstetric medicine. In response, a research team led by Associate Professor Satoshi Yoneda from the University of Toyama investigated a novel preventative strategy centered on the gut-immune axis. The study aims to reduce the number of children developing disabilities by introducing early-stage interventions for mothers identified as being at high risk for premature labor.

The Biological Link Between Gut Health and Pregnancy

The success of a pregnancy is largely dependent on a balanced maternal immune system that must tolerate a developing fetus while defending against external infections. This delicate equilibrium is maintained by regulatory T cells, which suppress excessive inflammatory responses that can trigger early labor. Recent research has suggested that specific intestinal bacteria, particularly Clostridium species, play a vital role in promoting these beneficial immune cells. Scientists have observed that women who experience spontaneous preterm delivery often exhibit significantly lower levels of these butyrate-producing bacteria, suggesting that restoring the gut microbiome could be a key factor in extending gestation.

Clinical Trial Results from Thirty-One Japanese Institutions

To test this hypothesis, researchers conducted a prospective multicenter clinical trial across 31 hospitals in Japan between 2021 and 2024. The study focused on pregnant women aged 18 to 43 who had previously experienced at least one spontaneous preterm delivery. Starting as early as 10 weeks into their pregnancy, participants were administered oral probiotic tablets three times daily. Each dose contained a specific combination of Clostridium butyricum, Enterococcus faecium, and Bacillus subtilis, with the regimen continuing until the final weeks of gestation.